Core Viewpoint - Johnson & Johnson's stock has recently exhibited a bullish technical pattern known as a Golden Cross, indicating potential long-term upside, supported by a significant breakthrough in lung cancer treatment [1][4]. Technical Analysis - The stock price of Johnson & Johnson is currently at $162.37, with short-term moving averages showing mixed signals. The 8-day simple moving average is at $163.37 and the 20-day simple moving average is at $164.45, indicating slight selling pressure. However, the 50-day simple moving average at $156.24 and the 200-day simple moving average at $155.72 support a bullish trend [1]. - The Moving Average Convergence Divergence (MACD) indicator stands at 1.74, reinforcing the bullish outlook, while the Relative Strength Index (RSI) is at 52.33, indicating the stock is in neutral territory [2]. Breakthrough in Cancer Treatment - Johnson & Johnson announced a significant milestone in lung cancer treatment, with the Phase 3 MARIPOSA study showing that the combination therapy of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) significantly improved survival rates for patients with advanced non-small cell lung cancer [2]. - The European Medicines Agency is considering approval for this breakthrough, which could serve as a long-term revenue driver for the company [3]. Investor Considerations - The Golden Cross pattern suggests a long-term bullish trend for Johnson & Johnson's stock, although short-term resistance levels may pose challenges. The combination of a promising cancer treatment and bullish technical signals provides both fundamental and technical reasons for investors to monitor the company closely [4].

General Motors Co GM is nearing a critical technical level that could trouble investors. Despite a promising partnership with Nvidia Corp NVDA to integrate AI into vehicle development, GM stock is approaching a Death Cross — a bearish signal that suggests potential downward momentum. Chart created using Benzinga ProGM Stock Chart Flashes CautionGM stock is teetering on the edge. The stock was trading at $49.16 at the time of writing, slipping below key moving averages:GM stock’s 50-day simple moving average ...

Core Viewpoint - JD.com is set to report its fourth-quarter earnings, with Wall Street expecting earnings per share (EPS) of 80 cents and revenues of $45.16 billion, indicating strong market anticipation for the results [1] Group 1: Stock Performance - JD.com stock has increased by 101.96% over the past year and 26.50% year-to-date [1] - The current stock price is $42.94, which is above key support levels, including the eight-day simple moving average at $41.31, the 20-day at $40.77, and the 50-day at $38.56, indicating a strong bullish trend [2] - The stock is also well above its 200-day simple moving average of $33.89, suggesting strong long-term support [3] Group 2: Technical Indicators - The Moving Average Convergence Divergence (MACD) indicator is at 0.78, indicating continued upward momentum [3] - The Relative Strength Index (RSI) is at 57.75, suggesting the stock is in neutral territory, allowing for further gains [3] Group 3: Analyst Ratings and Price Targets - The consensus analyst rating for JD.com stock is currently a Buy, with a price target of $42 [4] - Analysts from Barclays, Bernstein, and Citigroup have an average price target of $50.67, implying a potential upside of 16.76% for the stock [4] - At the time of publication, JD.com stock was up 6.35% at $43.55 [4]

Core Viewpoint - Salesforce Inc is set to report its fourth-quarter earnings, with Wall Street expecting an EPS of $2.61 and revenues of $10.04 billion, while the stock has shown a 2.76% increase over the past year but a 6.64% decline year-to-date [1] Stock Performance - Salesforce stock is currently priced at $308.35, indicating it is in bearish territory as it trades below its five-day, 20-day, and 50-day exponential moving averages (EMA), suggesting a strong downward trend [2] - The stock's eight-day simple moving average (SMA) is $316.35, the 20-day SMA is $328.28, and the 50-day SMA is $332.95, all reinforcing the bearish setup and short-term weakness [2] Technical Indicators - The stock remains above its 200-day SMA of $289.55, which provides a longer-term bullish signal [3] - Momentum indicators show a negative trend, with the Moving Average Convergence Divergence (MACD) at -6.90 indicating negative momentum, and the Relative Strength Index (RSI) at 34.92 suggesting the stock is nearing oversold conditions [3] Analyst Ratings - The consensus analyst rating for Salesforce stock is currently a Buy, with a price target of $378.03, indicating a potential upside of 26.57% according to recent ratings from Citigroup, Citizens Capital, and BMO Capital [5] - At the time of publication, Salesforce stock was trading at $308.12 [5]